1. Beck-Sagué C and Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980–1990: National Nosocomial Infections Surveillance System. J Infect Dis. 1993; 167:1247–51.
2. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 2005; 41:1232–9.
Article
3. Richardson MD. Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother. 2005; 56:i5–i11.
Article
4. Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J, et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991–2000. Clin Infect Dis. 2004; 38:311–20.
Article
5. Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: The NEMIS prospective multicenter study. Clin Infect Dis. 2001; 33:177–86.
Article
6. Asmundsdottir LR, Erlendsdottir H, Gottfredsson M. Increasing incidence of candidemia: Results from a 20-year nationwide study in Iceland. J Clin Microbiol. 2002; 40:3489–92.
Article
7. Tortorano AM, Peman J, Bernhardt H, Klingspor L, Kibbler CC, Faure O, et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis. 2004; 23:317–22.
Article
8. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Michael B. Nosocomial Bloodstream Infections in US Hospitals: Analysis of 24,179 Cases from a Prospective Nationwide Surveillance Study. Clin Infect Dis. 2004; 39:309–17.
Article
9. Korean Nosocomial Infections Surveillance System (KONIS). KONIS official report. http://www.kosnic.org/bbs/zboard.php?id=konisop/[Onine. ] (last visited on 16 October 2007).
10. Colombo AL, Nucci M, Park BJ, Noue´r SA, Arthington-Skaggs B, Matta DA, et al. Epidemiology of Candidemia in Brazil: a Nationwide Sentinel Surveillance of Candidemia in Eleven Medical Centers. J Clin Microbiol. 2006; 44:2816–23.
Article
11. Oho BJ, Choi HY, Lee JS, Cho D, Kee SJ, Shin MG, et al. Clinical and Laboratory Features of Candidemia Caused by Different Candida Species. Korean J Lab Med. 2005; 25:317–23.
12. Byun HW, Kim CH, Kim JK, Eom KS, Park YB, Jang SH, et al. A 5-year review of clinical characteristics and mortality of burn patients with candidemia in a tertiary burn center. Korean J Med. 2006; 70:298–308.
13. Kang BK, Lee HJ, Suh JT. The Trends of the Species and Antimicrobial Susceptibility of Bacteria and Fungi Isolated from Blood Cultures (1986–1996) Korean J Clin Pathol. 1998; 18:57–64.
14. Hsueh PR, Teng LJ, Yang PC, Ho SW, Luh KT. Emergence of nosocomial candidemia at a teaching hospital in Taiwan from 1981 to 2000: increased susceptibility of Candida species to fluconazole. Microb Drug Resist. 2002; 8:311–9.
15. Cheng YR, Lin LC, Young TG, Liu CE, Chen CH, Tsay RW. Risk factors for candidemia-related mortality at a medical center in central Taiwan. J Microbiol Immunol Infec. 2006; 39:155–61.
16. Viudes A, Pemán J, Cantón E, Úbeda P, López-Ribot JL, Gobernado M. Candidemia at a Tertiary-Care Hospital: Epidemiology, Treatment, Clinical Outcome and Risk Factors for Death. Eur J Clin Microbiol Infect Dis. 2002; 21:767–74.
Article
17. Yamamura DLR, Rotstein C, Nicolle LE. Candidemia at selected Canadian sites: results from the Fungal Disease Registry, 1992–1994. CMAJ. 1999; 160:493–9.
18. Takakura S, Fujihara N, Saito T, Kudo T, Iinuma Y, Ichiyama , et al. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J Antimicrob Chemother. 2004; 53:283–9.
Article
19. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP. National Nosocomial Infections Surveillance System Hospitals Clinical Infectious Diseases. Secular Trend of Hospital-Acquired Candidemia among Intensive Care Unit Patients in the United States during 1989–1999. Clin Inf Dis. 2002; 35:627–30.
20. Metwally L, Walker MJ, Coyle PV, Hay RJ, Hedderwick S, McCloskey BV, et al. Trends in candidemia and antifungal susceptibility in a university hospital in Northern Ireland 2001–2006. J Infect. 2007; 55:174–8.
Article
21. Lagrou K, Verhaegen J, Peetermans WE, De Rijdt T, Maertens J, Wijngaerden EV. Fungemia at a tertiary care hospital: incidence, therapy, and distribution and antifungal susceptibility of causative species. Eur J Clin Microbiol Infect Dis. 2007; 26:541–7.
Article
22. Sandven P, Bevanger L, Digranes A, Gaustad P, Haukland HH, Steinbakk M. Constant low rate of fungemia in Norway, 1991 to 1996. J Clin Microbiol. 1998; 36:3455–9.
Article
23. Snydman DR. Shifting Patterns in the Epidemiology of Nosocomial Candida Infections. Chest. 2003; 123:500S–3S.
Article
24. Warnock DW. Trends in the epidemiology of invasive fungal infections. Jpn J Med Mycol. 2007; 48:1–12.
Article
25. Clark TA, Slavinski SA, Morgan J, Lott T, Arthington-Skaggs BA, Brandt ME, et al. Epidemiologic and molecular characterization of an outbreak of Candida parapsilosis bloodstream infections in a community hospital. J Clin Microbiol. 2004; 42:4468–72.
26. Komshian SV, Uwaydah AK, Sobel JD, Crane LR. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis. 1989; 11:379–90.
Article
27. Almirante B, Rodriguez D, Cuenca-Estrella M, Almela M, Sanchez F, Ayats J, et al. Epidemiology, Risk Factors, and Prognosis of Candida parapsilosis Bloodstream Infections: Case-Control Population-Based Surveillance Study of Patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol. 2006; 44:1681–5.
28. Shin JH, Kim MN, Shin DH, Jung SI, Kim KJ, Cho D, et al. Genetic relatedness among Candida tropicalis isolates from sporadic cases of fungemia in two university hospitals in Korea. Infect Control Hosp Epidemiol. 2004; 25:634–40.